DK1626726T3 - Anvendelse af lornoxicam eller lornoxicam-analoger - Google Patents

Anvendelse af lornoxicam eller lornoxicam-analoger

Info

Publication number
DK1626726T3
DK1626726T3 DK04734972T DK04734972T DK1626726T3 DK 1626726 T3 DK1626726 T3 DK 1626726T3 DK 04734972 T DK04734972 T DK 04734972T DK 04734972 T DK04734972 T DK 04734972T DK 1626726 T3 DK1626726 T3 DK 1626726T3
Authority
DK
Denmark
Prior art keywords
lornoxicam
analogues
oxygenase
cox
cyclo
Prior art date
Application number
DK04734972T
Other languages
Danish (da)
English (en)
Inventor
Dieter Di Binder
Original Assignee
Binder Eva
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Binder Eva filed Critical Binder Eva
Application granted granted Critical
Publication of DK1626726T3 publication Critical patent/DK1626726T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK04734972T 2003-05-27 2004-05-27 Anvendelse af lornoxicam eller lornoxicam-analoger DK1626726T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0081903A AT413944B (de) 2003-05-27 2003-05-27 Verwendung von oxicam-verbindungen

Publications (1)

Publication Number Publication Date
DK1626726T3 true DK1626726T3 (da) 2006-12-27

Family

ID=33479909

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04734972T DK1626726T3 (da) 2003-05-27 2004-05-27 Anvendelse af lornoxicam eller lornoxicam-analoger

Country Status (13)

Country Link
US (2) US8129370B2 (fr)
EP (1) EP1626726B1 (fr)
JP (1) JP5597339B2 (fr)
KR (1) KR101134244B1 (fr)
CN (3) CN101450057A (fr)
AT (2) AT413944B (fr)
CA (1) CA2526816C (fr)
DE (1) DE502004001499D1 (fr)
DK (1) DK1626726T3 (fr)
ES (1) ES2271893T3 (fr)
PL (1) PL1626726T3 (fr)
RU (1) RU2366425C2 (fr)
WO (1) WO2004105766A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1740585B1 (fr) * 2004-04-29 2009-08-19 Binder, Eva HF Derives d'hexahydropyrrolocyclopentapyridine exempts d'enantiomeres
EP2365804B1 (fr) * 2008-11-13 2015-05-06 Modgene, Llc Reduction du taux d'amyloid beta dans des tissues autre que le cerveau
EP2776035B1 (fr) 2011-11-01 2016-08-10 Modgene, Llc Compositions et méthodes de réduction de la charge amyloïde-bêta
CN115227655A (zh) * 2022-08-17 2022-10-25 海南锦瑞制药有限公司 注射用氯诺昔康的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU518216B2 (en) * 1977-09-06 1981-09-17 Hafslund Nycomed Pharma Aktiengesellschaft Thienothiazine derivatives
JPS58146040A (ja) * 1982-02-24 1983-08-31 Pioneer Video Kk 光学式情報記録原盤
EP0103142B1 (fr) 1982-09-09 1987-04-22 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Dérivés de thiéno(2,3-e)-1,2-thiazine
NZ226477A (en) * 1987-10-29 1990-07-26 Cl Pharma Substituted thieno (2,3-e)-1,2 thiazine derivatives and pharmaceutical compositions
US5192753A (en) * 1991-04-23 1993-03-09 Mcgeer Patrick L Anti-rheumatoid arthritic drugs in the treatment of dementia
AT400437B (de) * 1993-12-14 1995-12-27 Chem Pharm Forsch Gmbh Neue n-heterocyclische thienothiazincarboxamide, verfahren zu ihrer herstellung und ihre verwendung
US5643960A (en) * 1994-04-15 1997-07-01 Duke University Method of delaying onset of alzheimer's disease symptoms
US6184248B1 (en) * 1996-09-05 2001-02-06 Robert K. K. Lee Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
US6043224A (en) * 1996-09-05 2000-03-28 The Massachusetts Institute Of Technology Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
CA2382547A1 (fr) * 1999-09-21 2001-03-29 Stephen R. Hanson Procedes et compositions de traitement des pathologies apparentees aux plaquettes
AU2001257022B2 (en) * 2000-04-13 2005-02-03 Mayo Foundation For Medical Education And Research Abeta 42 lowering agents
US6429223B1 (en) 2000-06-23 2002-08-06 Medinox, Inc. Modified forms of pharmacologically active agents and uses therefor
US20020119193A1 (en) * 2000-08-18 2002-08-29 Le Trang T. Oral fast-melt formulation of a cyclooxygenase-2 inhibitor
JP2002363104A (ja) 2001-04-04 2002-12-18 Sankyo Co Ltd 炎症性サイトカイン産生抑制剤の新規医薬用途
US7008614B2 (en) * 2001-08-20 2006-03-07 Fuji Photo Film Co., Ltd. Liposome containing hydrophobic iodine compound and X-ray contrast medium for radiograph comprising the liposome
US20030225054A1 (en) * 2002-06-03 2003-12-04 Jingwu Duan Combined use of tace inhibitors and COX2 inhibitors as anti-inflammatory agents

Also Published As

Publication number Publication date
WO2004105766A2 (fr) 2004-12-09
ATA8192003A (de) 2005-11-15
US8129370B2 (en) 2012-03-06
CA2526816C (fr) 2012-11-27
US20090239852A1 (en) 2009-09-24
US20070275958A1 (en) 2007-11-29
JP5597339B2 (ja) 2014-10-01
AT413944B (de) 2006-07-15
WO2004105766A3 (fr) 2005-03-03
PL1626726T3 (pl) 2007-02-28
JP2006528206A (ja) 2006-12-14
KR20060017618A (ko) 2006-02-24
RU2366425C2 (ru) 2009-09-10
DE502004001499D1 (de) 2006-10-26
ES2271893T3 (es) 2007-04-16
CA2526816A1 (fr) 2004-12-09
ATE339206T1 (de) 2006-10-15
CN101450057A (zh) 2009-06-10
CN102218067A (zh) 2011-10-19
EP1626726A2 (fr) 2006-02-22
EP1626726B1 (fr) 2006-09-13
KR101134244B1 (ko) 2012-04-09
CN1842338A (zh) 2006-10-04
RU2005136864A (ru) 2006-06-10

Similar Documents

Publication Publication Date Title
EA200301165A1 (ru) Лекарственное средство на основе оксикодона
CY1115719T1 (el) Νεοι φαρμακευτικοι συνδυασμοι για τη θεραπεια νοσων των αναπνευστικων οδων
CY1107146T1 (el) Μεθοδοι για προληψη και θεραπεια ασθενειας alzheimer (ad)
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
IS8485A (is) Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
EA200701175A1 (ru) Лекарственные средства, предназначенные для лечения или предупреждения фиброзных заболеваний
DE602004027936D1 (de) Tocopherolmodifizierte therapeutische arzneimittelverbindung
EA200601837A1 (ru) Бензоксазины для лечения заболеваний дыхательных путей
EA200401114A3 (ru) Замещённые гидроксиэтиламины
EA200701181A1 (ru) Лекарственные средства, предназначенные для лечения или предупреждения фиброзных заболеваний
CY1111567T1 (el) Ενδιαμεσα διβενζο (b,f) αζεπινης
TNSN06012A1 (en) Emulsifying systems containing azetidine derivatives
PA8568101A1 (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, y procedimientos para su uso
NO20076405L (no) Anvendelse av 24-nor-UDCA
CY1105317T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
CY1105142T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
EE200300129A (et) Distamütsiini alfa-halogenoakrüloüülderivaadi kasutamine
DE502004011919D1 (de) -trien-3-yl sulfamate
DK1626726T3 (da) Anvendelse af lornoxicam eller lornoxicam-analoger
MXPA06000636A (es) Formulaciones semi-solidas para la administracion oral de taxoides.
CY1106129T1 (el) Κιταλοπραμη για την αγωγη της υψηλης πιεσεως του αιματος
EA201000739A1 (ru) Новое медицинское применение солей 3-(2,2,2-триметилгидразиниум)пропионата
ITRM20000433A0 (it) Uso di fibrati per la preparazione di un medicamento utile nel trattamento dell'insufficenza cardiaca congestizia.
HUP0300032A2 (en) Use of compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoreceptor for preparation of pharmaceutical composition
DE60216090D1 (de) Verwendung von l-acetylcarnitin zur herstellung eines medikaments zur behandlung von anhedonia